ArticleThe journal of allergy and clinical immunology. In practice
Sinus surgery improves lower respiratory tract reactivity during aspirin desensitization for AERD.
Registry-linked trialAbstract readLetter
In one paragraph
Article in The journal of allergy and clinical immunology. In practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05246267 (Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis), which is not on this map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
Who cites it
14 citing papers in PubMed.
- Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.The World Allergy Organization journal · 2025Review
- Consultation for Chronic Rhinosinusitis With Nasal Polyps and Asthma: Clinical Presentation, Diagnostic Workup, and Treatment Options.The journal of allergy and clinical immunology. In practice · 2024Review
- [Expert consensus on the diagnosis and treatment of respiratory diseases exacerbated by nonsteroidal anti-inflammatory drugs （2024, Chengdu）].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2024Article
- Should Biologics Be Used Before Aspirin Desensitization in Aspirin-Exacerbated Respiratory Disease?The journal of allergy and clinical immunology. In practice · 2024Review
- Aspirin-exacerbated respiratory disease: Updates in the era of biologics.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2023Review
- Mechanistic and clinical updates in AERD: 2021-2022.The Journal of allergy and clinical immunology · 2023Article
- The role of oxylipins in NSAID-exacerbated respiratory disease (N-ERD).Advances in pharmacology (San Diego, Calif.) · 2023Article
- Mediator production and severity of aspirin-induced respiratory reactions: Impact of sampling site and body mass index.The Journal of allergy and clinical immunology · 2022Article
- Appraisal of the Real-World Effectiveness of Biologic Therapies in Aspirin-Exacerbated Respiratory Disease.The journal of allergy and clinical immunology. In practice · 2022Article
- Biomarkers for predicting response to long-term high dose aspirin therapy in aspirin-exacerbated respiratory disease.Clinical and translational allergy · 2021Review
- Biomarkers for predicting response to aspirin therapy in aspirin-exacerbated respiratory disease.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2021Article
- Scoring tool for systemic symptoms during aspirin challenge detects mediator production in aspirin-exacerbated respiratory disease.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2021Observational
- The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.The Journal of allergy and clinical immunology · 2021Review
- NSAID-ERD Syndrome: the New Hope from Prevention, Early Diagnosis, and New Therapeutic Targets.Current allergy and asthma reports · 2020Review
Corrections and comments
- Commented on by
Authors and funding
5 authors.
George X HuangDepartment of Medicine, Brigham and Women's Hospital, Boston, Mass.
Marina L PalumboDivision of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Mass.
Joseph I SingerDivision of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Mass.
Katherine N CahillDivision of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tenn.
Tanya M LaidlawDivision of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Mass. Electronic address: tlaidlaw@bwh.harvard.edu.
Funding
TRM and airway inflammation and remodelingU19AI070535 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROIDE, DAVID H · 2006 to 2025
$34.2MTherapeutic Control of Aspirin-Exacerbated Respiratory DiseaseU19AI095219 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Maria Gutierrez-Arcelus · 2011 to 2026
$29.1MRole of PGE2 in Human Mast Cell BiologyP01HL036110 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI STEVENS, RICHARD L · 1985 to 2009
$20.1MIMMUNOLOGIC BASIS OF RESISTANCE AND HYPERSENSITIVITYT32AI007306 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Nora Amanda Barrett, Joshua A Boyce · 1985 to 2026
$12.2MRegulation of Pulmonary Prostaglandins by Leukotriene E4R01AI078908 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI BOYCE, JOSHUA A · 2009 to 2025
$8.8MEicosanoid Networks in Aspirin HypersensitivityR01AI136041 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Joshua A Boyce · 2018 to 2026
$5.4MCysLT and P2Y Receptors in Lung InflammationR37AI052353 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI BOYCE, JOSHUA A · 2013 to 2022
$5.2MCystLT and P2Y Receptors and Lung InflammationR01AI052353 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI BOYCE, JOSHUA A · 2002 to 2012
$4.2MProstaglandin D2: A Key Mediator of Aspirin-Exacerbated Respiratory DiseaseR01HL128241 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LAIDLAW, TANYA MARIA · 2015 to 2019
$2.2MOptimizing EP receptor subtype targeting for asthma therapyR01HL136209 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI BIRRELL, MARK A, BOYCE, JOSHUA A · 2017 to 2020
$2.2MTHE ROLE OF PROSTAGLANDIN D2 IN THE RESPIRATORY SYMPTOMS OF ASPIRIN EXACERBATED RESPIRATORY DISEASEK23AI118804 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CAHILL, KATHERINE N · 2015 to 2019
$951kNHLBI NIH HHS P01 HL036110NHLBI NIH HHS R01 HL128241NHLBI NIH HHS R01 HL136209NIAID NIH HHS K23 AI118804NIAID NIH HHS R01 AI052353NIAID NIH HHS R01 AI078908NIAID NIH HHS R01 AI136041NIAID NIH HHS R37 AI052353NIAID NIH HHS T32 AI007306NIAID NIH HHS U19 AI070535NIAID NIH HHS U19 AI095219
Abstract
PubMed holds no abstract for this paper.
Indexed as
Desensitization, ImmunologicOtorhinolaryngologic Surgical ProceduresAdultAllergensAspirinAsthma, Aspirin-InducedEndoscopyFemaleForced Expiratory VolumeHumansMaleMiddle AgedNasal PolypsParanasal SinusesRetrospective StudiesSino-Nasal Outcome TestAllergensAspirin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT05246267ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.